BerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and Sobi®
Bergen, Norway, May 28, 2024, – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that it has entered into a clinical trial agreement with the Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and Swedish Orphan Biovitrum AB (Sobi®) (STO:SOBI), a specialized international biopharmaceutical company. The parties will collaborate to study BerGenBio’s selective AXL inhibitor, bemcentinib, in combination with Sobi’